No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo

References

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
   Google Scholar
• Klapper W. Histopathology of mantle cell lymphoma. Semin Hematol 2011;48:148–154.
   PubMed Web of Science ®Google Scholar
• Lukas J, Jadayel D, Bartkova J, et al. BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. Oncogene 1994;9:2159–2167.
   PubMed Web of Science ®Google Scholar
• Klier M, Anastasov N, Hermann A, et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008;22:2097–2105.
   PubMed Web of Science ®Google Scholar
• Tchakarska G, Le Lan-Leguen A, Roth L, et al. The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies. Haematologica 2009;94:1781–1782.
   PubMed Web of Science ®Google Scholar
• Tiemann K, Alluin JV, Honegger A, et al. Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines. Leuk Lymphoma 2011;52:2148–2154.
   PubMed Web of Science ®Google Scholar
• Weinstein S, Emmanuel R, Jacobi AM, et al. RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma. PloS One 2012;7:e43343.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Kluin-Nelemans HC, Bea S, et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma 2013;54:699–707.
   PubMed Web of Science ®Google Scholar
• Nodit L, Bahler DW, Jacobs SA, et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003;34:1030–1034.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010;115:3215–3223.
   PubMed Web of Science ®Google Scholar
• Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005;131:29–38.
   PubMed Web of Science ®Google Scholar
• Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385–2387.
   PubMed Web of Science ®Google Scholar
• Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006;107:3407.
   PubMed Web of Science ®Google Scholar
• Vogt N, Klapper W. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression. Histopathology 2013;62:334–342.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185–197.
   PubMed Web of Science ®Google Scholar
• Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematopathol 2009;2:103–111.
   PubMedGoogle Scholar
• Braun N, Papadopoulos T, Muller-Hermelink HK. Cell cycle dependent distribution of the proliferation-associated Ki-67 antigen in human embryonic lung cells. Virchows Arch B Cell Pathol Incl Mol Pathol 1988;56:25–33.
   PubMedGoogle Scholar
• Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710–1715.
   PubMed Web of Science ®Google Scholar
• Ott MM, Bartkova J, Bartek J, et al. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood 1997;90:3154–3159.
   PubMed Web of Science ®Google Scholar
• Shakir R, Ngo N, Naresh KN. Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma. J Clin Pathol 2008;61:920–927.
   PubMed Web of Science ®Google Scholar
• Abramov D, Oschlies I, Konovalov D, Damm et al. Intratumoral heterogeneity in anaplastic large cell lymphoma of non-common subtype. J Hematopathol 2012;5:109–116.
   Google Scholar
• Abramov D, Oschlies I, Zimmermann M, et al. Expression of CD8 is associated with non-common type morphology and outcome in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica 2013;98:1547–1553.
   PubMed Web of Science ®Google Scholar
• Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580–584.
   PubMed Web of Science ®Google Scholar
• Martinez A, Bellosillo B, Bosch F, et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004;164:501–510.
   PubMed Web of Science ®Google Scholar
• Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2008;30:117–122.
   PubMed Web of Science ®Google Scholar
• User Bulletin #2: ABI PRISM 7700 Sequence Detection System. Life Technologies, Darmstadt, Germany, 2001.
   Google Scholar
• Rudolph P, Knuchel R, Endl E, et al. The immunohistochemical marker Ki-S2: cell cycle kinetics and tissue distribution of a novel proliferation-specific antigen. Mod Pathol 1998;11:450–456.
   PubMed Web of Science ®Google Scholar
• Tiemann M, Claviez A, Luders H, et al. Proliferation characteristics in pediatric Hodgkin’s lymphoma point to a cell cycle arrest in the G(1) phase. Mod Pathol 2005;18:1440–1447.
   PubMed Web of Science ®Google Scholar
• Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007;109:4599–4606.
   PubMed Web of Science ®Google Scholar
• Mohanty A, Sandoval N, Bedell V, et al. Cyclin D1 maintains mantle cell lymphoma through CDK4-independent regulation of DNA replicative checkpoints. Blood 2013;122(Suppl. 1): Abstract 2512.
   Google Scholar
• Liu H, Huang J, Wang J, et al. Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma. J Exp Med 2008;205:1843–1858.
   PubMed Web of Science ®Google Scholar
• Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499–3511.
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:26–38.
   PubMed Web of Science ®Google Scholar
• Baldin V, Lukas J, Marcote MJ, et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993;7:812–821.
   PubMed Web of Science ®Google Scholar
• Pagano M, Theodoras AM, Tam SW, et al. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 1994;8:1627–1639.
   PubMed Web of Science ®Google Scholar
• Stuart A, Shimko S, Epner EM. Crosstalk between cyclins D1 and D3 in mantle cell level at the transcriptional and postranscriptional levels. Blood 2011;118(Suppl. 1): Abstract 1373.
   Google Scholar
• Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996;87:4302–4310.
   PubMed Web of Science ®Google Scholar
• Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996;87:3351–3359.
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Davies-Hill T, Fend F, et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 2003;101:3181–3187.
   PubMed Web of Science ®Google Scholar
• Ek S, Bjorck E, Porwit-MacDonald A, et al. Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. Haematologica 2004;89:686–695.
   PubMed Web of Science ®Google Scholar
• Slotta-Huspenina J, Koch I, de Leval L, et al. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica 2012;97:1422–1430.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Zettl A, Bea S, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007;25:1216–1222.
   PubMed Web of Science ®Google Scholar
• Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008;142:149–165.
   PubMed Web of Science ®Google Scholar